Skip to main content

Table 3 Sociodemographic, biochemical, enzymatic, genetic and clinical information on 88 patients with MCC deficiency 8 individuals identified by family screening (asymptomatic individuals (n = 3), symptomatic individuals (n = 3), no clinical data (n = 2))

From: 3-methylcrotonyl-CoA carboxylase deficiency: Clinical, biochemical, enzymatic and molecular studies in 88 individuals

Pt #

Sex

Ethnic origin

Age at diagnosis

Current age (y)

Biochemical phenotype

Carboxylase activities in fibroblasts (pmol/min/ mg protein)1

Genotype

Clinical phenotype§

DBS/ plasma

urine

affected gene

Nucleotide change (at RNA level)

Amino acid change (predicted from RNA)

C5OH

3-HIVA

3MCG

MCC

PCC

Allele 1 Allele 2

32b

m

Arab

17 years

28

++

++

++

5.3

409

na

na

na

asymptomatic (fr)

93a

m

Caucasian

4 years

12

++

+

+

19.0

402

MCCC1

c.558delA

p.Q186Hfs*6

asymptomatic (ltf)

           

c.558delA

p.Q186Hfs*6

 

99b

f

Turkish

5.5 years

8

++

++

++

na

na

na

na

na

asymptomatic (fr)

70b

m

Caucasian

3.5 years

10

+

+

++

na

na

na

na

na

speech retardation, muscle weakness, hyperactivity, refusal of meat (fr)

96c

m

Turkish

3 years

8

++

++

++

na

na

MCCC1

c.873+4524_ 6787del2264

large deletion

mild speech retardation, macrocephaly (ltf)

           

c.873+4524_ 6787del2264

large deletion

 

35b

f

Caucasian

18 months

18

na

++

++

na

na

na

na

na

psychomotor retardation (by 2 years developmental age of 10 months), failure to thrive, hypothermia and ketonuria prior to stabilisation on dietary therapy (ltf, 1.75y)

52b

m

Turkish

?

?

na

na

na

na

na

MCCC2

c.803G>C

p.R268T

?

           

(r.785_803del)

(p.G262_ R268delfs*5)

 
           

c.803G>C

p.R268T

 
           

(r.785_803del)

(p.G262_ R268delfs*5)

 

52c

m

Turkish

?

?

na

na

na

na

na

MCCC2

c.803G>C

p.R268T

?

           

(r.785_803del)

(p.G262_ R268delfs*5)

 
           

c.803G>C

p.R268T

 
           

(r.785_803del)

(p.G262_ R268delfs*5)

 
  1. 1 control values measured in 53 cell lines, expressed as median value and (range): MCC activity, 305 pmol/min/mg protein (134-671); PCC activity, 583 (208-1165); ratio of PCC/MCC activity, 1.93 (1.19 – 2.58).
  2. §information in brackets: fr followed regularly, ltf lost to follow-up, age of last follow-up, if known. + slightly elevated; ++ massively elevated; C5OH 3-hydroxyisovalerylcarnitine; DBS dried blood spots; 3-HIVA 3-hydroxyisovaleric acid; 3-MCG 3-methylcrotonylglycine; f female; fr followed regularly; ltf lost to follow-up; m male; MCC methylcrotonyl-CoA carboxylase; n normal; na not available; NBS newborn screening; PCC propionyl-CoA carboxylase; Pt # Patient number; RNA nd RNA not detectable; SMS selective metabolic screening; y years; mutation heterozygous on genomic PCR, homozygous in RT-PCR; # diagnosed following the positive NBS result of their baby; ? not known.